RPS6KL1 Inhibitors
RPS6KL1 inhibitors encompass a diverse array of chemical compounds that interfere with various signaling pathways, ultimately leading to the inhibition of RPS6KL1 activity. For instance, certain small molecule inhibitors target the upstream kinases in the MAPK/ERK pathway, resulting in the suppression of downstream effectors including RPS6KL1. By preventing the phosphorylation and activation of these upstream kinases, these compounds indirectly diminish thekinase activity of RPS6KL1, which is crucial for its role in cellular functions such as growth and metabolism. Similarly, other inhibitors act on the PI3K/AKT/mTOR signaling axis, a critical pathway modulating cell survival and proliferation. These inhibitors, by blocking PI3K or mTOR, the central kinase in this pathway, exert a downstream inhibitory effect on RPS6KL1. Some compounds specifically inhibit mTORC1 and mTORC2 complexes, both of which are implicated in the regulation of RPS6KL1, thereby curtailing its kinase activity. Additionally, the inhibition of related kinases such as p70 S6 kinase 1, which shares the mTOR signaling pathway with RPS6KL1, can also result in a decrease in RPS6KL1 signaling due to the interconnected nature of these pathways.
The array of inhibitors that modulate RPS6KL1 activity also includes those that thwart kinases like p38 MAP kinase and c-Jun N-terminal kinase (JNK), which are involved in stress and inflammatory responses. By impeding the activity of these kinases, the inhibitors can indirectly influence the functional state of RPS6KL1, as these kinases interact with the mTOR pathway, which is integral to RPS6KL1's regulation. Inhibition of JNK, for example, has implications for the modulation of the mTOR pathway, and by extension, RPS6KL1 activity. Furthermore, targeting the PI3K/AKT/mTOR pathway with different chemical structures that share the common feature of PI3K inhibition also results in a reduction of RPS6KL1 activity. The specificity of these compounds for their target kinases ensures precise modulation of the signaling pathways, thereby achieving a targeted decrease in RPS6KL1 activity without affecting unrelated cellular processes.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
This compound is a specific inhibitor of mitogen-activated protein kinase kinase (MEK), which is upstream of the extracellular signal-regulated kinase (ERK) pathway. Inhibition of MEK leads to a decrease in ERK phosphorylation and activity, which can downregulate RPS6KL1 activity, as the kinase is a downstream effector in the ERK signaling pathway. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A potent inhibitor of phosphoinositide 3-kinases (PI3K), which blocks the PI3K/AKT/mTOR signaling pathway. Since RPS6KL1 is part of the mTOR signaling network, inhibition of this pathway by LY 294002 can suppress RPS6KL1 activity due to reduced signaling through mTOR. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
This macrolide compound inhibits the mechanistic target of rapamycin (mTOR), a kinase that is central to cell growth and metabolism. RPS6KL1 is involved in the mTOR signaling pathways; thus, inhibition by rapamycin can lead to reduced RPS6KL1 kinase activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A pyridinyl imidazole compound that selectively inhibits p38 MAP kinase. Through the inhibition of p38 MAP kinase, SB 203580 can reduce RPS6KL1 activity indirectly, as p38 has been implicated in regulating the mTOR pathway and associated kinases. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
An inhibitor of PI3K, wortmannin leads to inhibition of the AKT/mTOR pathway. RPS6KL1, being a downstream effector in this signaling pathway, will have decreased activity in response to wortmannin due to the suppression of the pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An anthrapyrazolone inhibitor of c-Jun N-terminal kinase (JNK), which is involved in a range of cellular processes. By inhibiting JNK, SP600125 can indirectly affect RPS6KL1 activity as JNK can modulate mTOR signaling, thereby affecting kinases like RPS6KL1. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
A selective inhibitor of MEK1/2, which prevents activation of ERK1/2. Since RPS6KL1 is a downstream effector in the ERK pathway, inhibition of MEK1/2 by U0126 can lead to decreased activation and function of RPS6KL1. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
A tricyclic nucleoside which inhibits the AKT/mTOR pathway. As RPS6KL1 function is influenced by mTOR signaling, triciribine can lead to a reduction in RPS6KL1 activity by blocking this critical pathway. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $163.00 $352.00 | 12 | |
A potent inhibitor of mTOR kinase, which affects both mTORC1 and mTORC2 complexes. By inhibiting mTOR, AZD8055 can lead to a decrease in RPS6KL1 kinase activity, as RPS6KL1 is regulated by mTOR-dependent signaling. | ||||||
PF 4708671 | 1255517-76-0 | sc-361288 sc-361288A | 10 mg 50 mg | $179.00 $700.00 | 9 | |
A selective inhibitor of p70 S6 kinase 1 (S6K1), which operates downstream of mTOR. While RPS6KL1 is distinct from S6K1, inhibition of S6K1 by PF 4708671 can lead to reduced mTOR signaling, potentially affecting RPS6KL1 activity. | ||||||